As of November 6, 2026, Sagimet Biosciences Inc. is a publicly traded company (Nasdaq: SGMT); its largest reported holder is BlackRock, with 7.8% on Schedule 13G of July 30, 2026, then Commodore Capital (7.6%). The largest insider holding is David Happel, the chief executive and president, with 741,570 shares (2.4% of shares outstanding), per Form 4 of July 22, 2026 (Schedule 13G, July 30, 2026).
Is this your company?
About to sign with, pay or invest in Sagimet Biosciences Inc.? See the free Snapshot first.
Free to see. No signup.
Is Sagimet Biosciences Inc. a real, registered company?
- Sagimet Biosciences Inc. files with the SEC under CIK 1400118 (its SEC filings).
- Its shares are listed under the ticker SGMT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Foster City, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Sagimet Biosciences Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Tim Walbert, Director (Form 8-K filed 2026-06-12). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Commodore Capital (filed 2026-10-07).
Who are Sagimet Biosciences Inc.'s owners and officers?
Sagimet Biosciences Inc.: incorporated in Delaware; business address in Foster City, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-07).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-07 | Commodore Capital LP | 7.6% |
| Schedule 13G, 2026-08-14 | Balyasny Asset Management L.P. | 5.93% |
| Schedule 13G, 2026-07-30 | Blackrock, Inc. | 7.8% |
| Schedule 13G/A, 2025-12-18 | Kpcb Pandemic And Bio Defense Fund, LLC | 0% |
| Schedule 13G/A, 2025-11-14 | Woodline Partners LP | 4.8% |
| Schedule 13G/A, 2025-08-14 | Point72 Asset Management, L.P. | 0% |
| Schedule 13G, 2025-08-14 | Woodline Partners LP | 8.3% |
Questions about who owns Sagimet Biosciences Inc.
Who owns Sagimet Biosciences Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Sagimet Biosciences Inc.: Blackrock, Inc. (7.8%, Schedule 13G, filed 2026-07-30), Commodore Capital LP (7.6%, Schedule 13G, filed 2026-10-07) and Balyasny Asset Management L.P. (5.93%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Sagimet Biosciences Inc.?
By the share each holder's latest filing reports, the largest holders of Sagimet Biosciences Inc. on this page are Blackrock, Inc. (7.8%), Commodore Capital LP (7.6%) and Balyasny Asset Management L.P. (5.93%).
When did Blackrock, Inc. buy into Sagimet Biosciences Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G, filed 2026-07-30, reporting 7.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Sagimet Biosciences Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Sagimet Biosciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sagimet Biosciences Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-12 | Tim Walbert | Director | departed | 2026-06-12 |
Which insiders own Sagimet Biosciences Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 741,570 shares (2.4% of shares outstanding) (Form 4, 2026-07-22).
- , the chief legal and admin. officer: 224,414 shares (0.73% of shares outstanding) (Form 4, 2026-07-22).
- , the chief medical officer: 147,296 shares (0.48% of shares outstanding) (Form 4, 2026-02-20).
- , a director: 62,161 shares (0.20% of shares outstanding) (Form 4, 2026-08-17).
- , the chief financial officer: 59,688 shares (0.19% of shares outstanding) (Form 4, 2026-02-20).
Shares outstanding: 30,674,855 as of 2024-11-08, from the company's latest SEC cover page.
How much has Sagimet Biosciences Inc. raised?
No fundraising or offering filing from Sagimet Biosciences Inc. is on file with us.
Keep reading
More on Sagimet Biosciences Inc. and the records around it.
Sagimet Biosciences Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- BALYASNY ASSET MANAGEMENT L.P. also filed stake reports on 31 other companies: Beyond Air, Inc. (Aug 2026), Camp4 Therapeutics Corp. (Aug 2026), CELLECTAR BIOSCIENCES, INC. (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026), InflaRx N.V. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/sagimet-biosciences